Burr, Lucy

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 726

A novel microbiota stratification system predicts future exacerbations in bronchiectasis

Rogers, G. B., Zain, N. M. M., Bruce, K. D., Burr, L. D., Chen, A. C., Rivett, D. W., McGuckin, M. A., & Serisier, D. J. (2014) · Annals of the American Thoracic Society

Cystic Fibrosis Research AdvancesBacterial biofilms and quorum sensing

Cited by 244

The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial

Rogers, G. B., Bruce, K. D., Martin, M. L., Burr, L. D., & Serisier, D. J. (2014) · The Lancet Respiratory Medicine

Cystic Fibrosis Research AdvancesMycobacterium research and diagnosis

Cited by 217